By IPP Bureau - March 04, 2024

Launch of Indian public health standards for Ayush healthcare facilities

By IPP Bureau - March 04, 2024

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30

By IPP Bureau - March 04, 2024

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research

By IPP Bureau - March 04, 2024

With this, the total number of Patents granted to company for its innovative processes and technology stands at 9

By IPP Bureau - March 03, 2024

EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility

By IPP Bureau - March 03, 2024

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg

By IPP Bureau - March 02, 2024

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently

By IPP Bureau - March 02, 2024

The product will be launched in March 2024

By IPP Bureau - March 02, 2024

The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra

By IPP Bureau - March 02, 2024

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness

By IPP Bureau - March 02, 2024

Cipla completes transfer of Generics Business Undertaking

By IPP Bureau - March 01, 2024

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals

By IPP Bureau - March 01, 2024

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

By IPP Bureau - March 01, 2024

Eugia Pharma Specialities restarts production at terminally sterilized product lines

By IPP Bureau - March 01, 2024

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth